[1] Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial [J]. Jama, 2019, 321(13): 1261-1274. doi:10.1001/jama.2019.0693.
[2] Latchamsetty R, Morady F. Atrial Fibrillation Ablation [J]. Annu Rev Med, 2018, 69: 53-63. doi:10.1146/annurev-med-041316-090015.
[3] Brooks AG, Stiles MK, Laborderie J, et al. Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review [J]. Heart Rhythm, 2010, 7(6): 835-846. doi:10.1016/j.hrthm.2010.01.017.
[4] Buist TJ, Zipes DP, Elvan A. Atrial fibrillation ablation strategies and technologies: past, present, and future [J]. Clin Res Cardiol, 2021, 110(6): 775-788. doi:10.1007/s00392-020-01751-5.
[5] Gluvic Z, Zaric B, Resanovic I, et al. Link between Metabolic Syndrome and Insulin Resistance [J]. Curr Vasc Pharmacol, 2017, 15(1): 30-39. doi:10.2174/1570161114666161007164510.
[6] Ahn HJ, Han KD, Choi EK, et al. Cumulative burden of metabolic syndrome and its components on the risk of atrial fibrillation: a nationwide population-based study [J]. Cardiovasc Diabetol, 2021, 20(1): 20. doi:10.1186/s12933-021-01215-8.
[7] Creta A, Providência R, Adragão P, et al. Impact of Type-2 Diabetes Mellitus on the Outcomes of Catheter Ablation of Atrial Fibrillation (European Observational Multicentre Study) [J]. Am J Cardiol, 2020, 125(6): 901-906. doi:10.1016/j.amjcard.2019.12.037.
[8] Nattel S. Molecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation [J]. JACC Clin Electrophysiol, 2017, 3(5): 425-435. doi:10.1016/j.jacep.2017.03.002.
[9] Polovina M, Krljanac G, Ašanin M, et al. Crouching tiger, hidden dragon: insulin resistance and the risk of atrial fibrillation [J]. Eur J Prev Cardiol, 2020, 27(18): 1931-1933. doi:10.1177/2047487320912626.
[10] Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms [J]. Circ Res, 2014, 114(9): 1453-1468. doi:10.1161/circresaha.114.303211.
[11] Hsu JC, Maddox TM, Kennedy KF, et al. Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry [J]. JAMA Cardiol, 2016, 1(1): 55-62. doi:10.1001/jamacardio.2015.0374.
[12] Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man [J]. Diabetologia, 1985, 28(7): 412-419. doi:10.1007/bf00280883.
[13] Dong JZ, Sang CH, Yu RH, et al. Prospective randomized comparison between a fixed '2C3L' approach vs. stepwise approach for catheter ablation of persistent atrial fibrillation [J]. Europace, 2015, 17(12): 1798-1806. doi:10.1093/europace/euv067.
[14] Hammoudeh AJ, Khader Y, Kadri N, et al. Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study [J]. Int J Vasc Med, 2021, 2021: 5515089. doi:10.1155/2021/5515089.
[15] Fujino T, Yuzawa H, Kinoshita T, et al. Clinical Factors Associated with a Successful Catheter Ablation Outcome in Elderly Patients with Atrial Fibrillation [J]. Int Heart J, 2020, 61(1): 21-28. doi:10.1536/ihj.19-226.
[16] Bajraktari G, Bytyçi I, Henein MY. Left atrial structure and function predictors of recurrent fibrillation after catheter ablation: a systematic review and meta-analysis [J]. Clin Physiol Funct Imaging, 2020, 40(1): 1-13. doi:10.1111/cpf.12595.
[17] Hijioka N, Kamioka M, Matsumoto Y, et al. Clinical impact of insulin resistance on pulmonary vein isolation outcome in patients with paroxysmal atrial fibrillation [J]. J Cardiovasc Electrophysiol, 2019, 30(4): 479-486. doi:10.1111/jce.13827.
[18] Ndisang JF, Vannacci A, Rastogi S. Insulin Resistance, Type 1 and Type 2 Diabetes, and Related Complications 2017 [J]. J Diabetes Res, 2017, 2017: 1478294. doi:10.1155/2017/1478294.
[19] Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions [J]. Diabetes Care, 2003, 26(3): 575-581. doi:10.2337/diacare.26.3.575.
[20] Xing XY,Yang WY,Yang ZJ.The diagnostic significance of homeostasis model assessment of insulin resistance in metabolic syndrome among subjects with different glucose tolerance.J Diabetes. 2004 May;12(3):182-186.
[21] Tang Q, Li X, Song P, et al. Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research and prospects for the future [J]. Drug Discov Ther, 2015, 9(6): 380-385. doi:10.5582/ddt.2015.01207.
[22] Park YJ, Han SM, Huh JY, et al. Emerging roles of epigenetic regulation in obesity and
metabolic disease [J]. J Biol Chem, 2021: 101296. doi:10.1016/j.jbc.2021.101296.
[23] Sivasambu B, Balouch MA, Zghaib T, et al. Increased rates of atrial fibrillation recurrence following pulmonary vein isolation in overweight and obese patients [J]. J Cardiovasc Electrophysiol, 2018, 29(2): 239-245. doi:10.1111/jce.13388.
[24] Middeldorp ME, Ariyaratnam J, Lau D, et al. Lifestyle modifications for treatment of atrial fibrillation [J]. Heart, 2020, 106(5): 325-332. doi:10.1136/heartjnl-2019-315327.
[25] Maria Z, Campolo AR, Scherlag BJ, et al. Dysregulation of insulin-sensitive glucose transporters during insulin resistance-induced atrial fibrillation [J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt A): 987-996. doi:10.1016/j.bbadis.2017.12.038.
[26] Shigematsu Y, Hamada M, Nagai T, et al. Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy: association with insulin resistance [J]. J Cardiol, 2011, 58(1): 18-25. doi:10.1016/j.jjcc.2011.03.001.
[27] Lee Y, Cha SJ, Park JH, et al. Association between insulin resistance and risk of atrial fibrillation in non-diabetics [J]. Eur J Prev Cardiol, 2020, 27(18): 1934-1941. doi:10.1177/2047487320908706.
[28] Chao TF, Suenari K, Chang SL, et al. Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose [J]. Am J Cardiol, 2010, 106(11): 1615-1620. doi:10.1016/j.amjcard.2010.07.038.